



SHORT REPORT

Open Access

# Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells

Nina V Fuchs<sup>1,4\*</sup>, Sabine Loewer<sup>2,3†</sup>, George Q Daley<sup>2</sup>, Zsuzsanna Izsvák<sup>4</sup>, Johannes Löwer<sup>1\*</sup> and Roswitha Löwer<sup>1</sup>

## Abstract

**Background:** Malignant human embryonal carcinoma cells (ECCs) rely on similar transcriptional networks as non-malignant embryonic stem cells (ESCs) to control self-renewal, maintain pluripotency, and inhibit differentiation. Because re-activation of silenced *HERV-K(HML-2)* loci is a hallmark of ECCs, we asked if this HERV group was also reactivated in ESCs and induced pluripotent stem cells (iPSCs).

**Findings:** Using RT-PCR and Western Blot, we demonstrate *HERV-K(HML-2)* RNA and protein expression in undifferentiated human ESCs and iPSCs. Induction of differentiation by embryoid body formation resulted in rapid silencing of *HERV-K(HML-2)* provirus expression. Sequencing analysis of a conserved region of the *gag* gene showed that proviral expression in ESCs and iPSCs represents at least 11 of the 66 nearly full length *HERV-K(HML-2)* loci, with slightly varying patterns in individual cell lines. These proviruses are human specific integrations and harbor promoter competent long terminal repeats (LTR5hs subgroup). We observed high mRNA levels of the NP9 and Gag encoding proviruses *K101(22q11.21)* in all and *K10(5q33.3)* in most of the ECC, ESC, and iPSC lines tested, while *K37(11q23.3)* mRNA was detected only in ESCs and iPSCs. In addition, we detected expression of proviral mRNA encoding the RNA export adaptor Rec in all cell lines studied. Proviral mRNA originating from the *K108(7p22.1)* locus, which inter alia codes for functional Rec and Env proteins, was only reactivated in malignant ECC lines, not in benign ESCs or iPSCs.

**Conclusions:** *HERV-K(HML-2)* RNA and protein expression is a marker for pluripotent human stem cells. Initiation of differentiation results in rapid down-regulation. Further studies are needed to explore a putative functional role of *HERV-K(HML-2)* RNA and proteins in pluripotent stem cells.

**Keywords:** Human embryonic stem cells, Induced pluripotent stem cells, Activation of human endogenous retrovirus K proviruses, Embryoid body differentiation, Pluripotency marker

## Findings

Although no infectious HERV particles have been detected to date, several proviruses of the evolutionary young hominoid group *HERV-K(HML-2)* harbor open reading frames for viral proteins, as well as promoter competent long terminal repeats (LTRs) [1,2]. Two subgroups exist (Figure 1A): Type 2 proviruses encode the accessory

protein Rec, which mediates nuclear-cytoplasmic translocation of incompletely spliced RNA, thereby allowing translation of viral proteins [3]. Type 1 proviruses harbor a 292-bp deletion within the pol-env boundary, resulting in loss of a functional open reading frame for Rec, but gaining a functional open reading frame for the accessory protein Np9 [4]. *In vitro* assays have shown that Rec and Np9 interact with cellular proteins like the promyelocytic leukemia zinc finger protein (PLZF), ligand of numb protein X (LNx), testicular zinc-finger protein, androgen receptor, and small glutamine-rich tetratricopeptide repeat protein and might thus support cell transformation [5-9]. Although *HERV-K(HML-2)* proviruses may be transcribed in somatic cells [10,11], up-regulated transcription and


\* Correspondence: nina.fuchs@pei.de; johannes.loewer@pei.de

† Equal contributors

<sup>1</sup>Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Str. 51-59, D- 63225 Langen, Germany

<sup>4</sup>Mobile DNA, Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, D- 13092 Berlin, Germany

Full list of author information is available at the end of the article



protein expression, formation of retrovirus particles, and induction of an anti-*HERV-K(HML-2)* immune response are predominantly associated with germ cell tumors, embryonal carcinoma cell (ECC) lines, melanomas and other cancers [12-17].

The phenotype and transcriptional profile of ECCs resemble that of non-malignant pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) in that they express key pluripotency factors such as *OCT4*, *NANOG* and *SOX2* and other markers characteristic of pluripotent stem cells [reviewed in [21]]. In addition, ECCs rely on similar pathways to regulate self-renewal and inhibition of differentiation [21], such as autocrine FGF signalling and activation of downstream

signalling cascades, especially the ERK/MEK pathway [22,23]. These similarities prompted us to test whether *HERV-K(HML-2)* RNA and protein expression, which is a marker of ECCs, might also be reactivated in non-malignant pluripotent stem cells.

#### *HERV-K(HML-2)* RNA and proteins are expressed in ESCs and iPSCs

We analyzed the expression of *HERV-K(HML-2)* in three ESC lines (H1, H9, BG01), three fibroblast lines (MRC5, MSC, hFib2) and iPSC lines derived from these fibroblasts. All materials and methods are described in detail in Additional file 1 "Materials and Methods". To augment the probability to detect *HERV-K(HML-2)* transcripts

derived from proviral promoters, we analyzed completely spliced viral RNA by RT-PCR. Full length and spliced transcripts and the location of all primer pairs used are depicted in Figure 1B. We verified expression of the endogenous pluripotency genes *OCT4* and *NANOG* and absence of the differentiation marker gene *LMNA* in pluripotent stem cells, *ACTB* specific amplicons served as internal controls [19,20]. We did not detect any *HERV-K(HML-2)* specific amplicons in any of the fibroblast cell lines, which readily expressed the differentiation marker *LMNA*. In contrast, all ESC and iPSC lines tested showed expression of all three types of completely spliced *HERV-K(HML-2)* transcripts, in addition to the pluripotency markers *OCT4* and *NANOG* (Figure 1C). The intensities of the PCR amplicons varied between individual ESC/iPSC lines, suggesting differential activation of proviruses between lines.

The presence of spliced *HERV-K(HML-2)* type 2 transcripts in all pluripotent stem cell lines tested prompted us to investigate whether they encode functional Rec protein and thus enable translation of *HERV-K(HML-2)* Gag and Env proteins. Using a *HERV-K(HML-2)* Gag specific monoclonal antibody in Western blot analysis, we indeed detected low to moderate levels of this protein in the H9 ESCs and the hFib2-iPS5 iPSC line, but not in the parental fibroblasts hFib2. By contrast, the ECC line GH showed high levels of Gag protein expression (Figure 1D). To ensure the phenotypic similarity between the malignant ECC line and the non-malignant ESC/iPSC lines, we verified by RT-PCR that GH cells expressed the pluripotency markers *OCT4*, *NANOG*, *SOX2*, *STELLA* as well as the autocrine signaling factor *FGF4* (data not shown). The differences in *HERV-K(HML-2)* Gag protein levels observed in H9 and hFib2-iPS5 correlated with the differences in signal intensities of their *rec* specific amplicons in RT-PCRs (Figure 1C, compare intensities of amplicons 3), which is consistent with the idea that the


levels of functional Rec protein determine the efficiency of Gag protein translation.

#### Differentiation induces silencing of *HERV-K(HML-2)* proviruses

To determine whether *HERV-K(HML-2)* expression in pluripotent stem cells changes during differentiation, we induced embryoid body formation of hFib2-iPS5 cells. We applied semi-qRT-PCR analysis using the primer pair K7/K21 (see Figure 1B). Interestingly, the levels of *HERV-K(HML-2)* RNA started to decrease from day 6 onwards in hFib2-iPS5 cells, concomitant with a decrease of *NANOG* and an increase of *LMNA* expression (Figure 2A). To estimate the degree of the changes we quantified the signal intensities of the RT-PCR bands visualized by ethidium bromide gel analysis (Figure 2A) relative to *ACTB* (see Additional file 1 "Materials and Methods"). *HERV-K(HML-2)* expression levels dropped from 100% on day 0 to roughly 50% on day 6, and to 20% on day 10. Similarly, *NANOG* expression levels decreased from 100% on day 0 to roughly 75% on day 6, and 55% on day 10.

To verify this with a second method and cell line, we performed real-time RT-PCR analysis using differentiating H9 ESCs [19,20]. This analysis showed an even more dramatic reduction of *HERV-K(HML-2)* RNA expression during differentiation with significantly reduced transcription already detectable on day 2 of embryoid body differentiation (Figure 2B). Remarkably, the kinetics of *HERV-K(HML-2)* downregulation is even faster than repression of *OCT4* and *NANOG*.

These slightly divergent results may simply reflect the greater accuracy of real time PCR compared to semi-quantitative PCR or may be rooted in the well-known subtle differences in the expression profiles of pluripotent stem cells especially those of ESC compared to iPSC lines [24].



**Figure 2** *HERV-K(HML-2)* expression is immediately down-regulated during embryoid body differentiation. **A)** Semi-quantitative RT-PCR of *HERV-K(HML-2)* expression in hFib2- iPS5 cells using the primer pair K21 and K7. The faint band at  $\approx 570$  bp presumably represents the *rec* mRNA of provirus ERVK-17 (see Table 1) which contains a small deletion in the amplified region. *LMNA* was amplified using an alternative primer (see Additional file 1 "Materials and Methods") **B)** Quantitative expression analysis of *HERV-K(HML-2)* *env*, *rec* and *Np9* transcripts in H9 cells. *OCT4*, *LMNA*, and *ACTB* serve as control [19,20]. RNA levels are depicted relative to undifferentiated cells on day 0 ( $n=2$ , error bars  $+/-$ s.e.m).

The recent findings that high RNA levels of the endogenous retrovirus group *HERV-H* [25] and expression of non-LTR retrotransposons [26] are also associated with human pluripotent stem cells indicate that a pluripotent phenotype might be accompanied by a general relieve of retroelement silencing. We therefore asked whether re-activation of *HERV-K(HML-2)* proviruses is specific for certain proviral elements or occurs in a stochastic manner.

#### ***HERV-K(HML-2)* proviruses are activated in ESC/iPSC/ECC lines in varying patterns**

We analyzed activation of *HERV-K(HML-2)* proviruses in malignant and non-malignant pluripotent stem cells using an established protocol [27] to amplify, clone, and sequence a highly conserved part of the *gag* gene (see Additional file 1 “Materials and Methods”). A proviral sequence was scored as the genomic origin of the respective clone when the two sequences exerted more than 98% identity (Additional file 2 “Alignments”, .msf files

of these alignments are available as Additional files 3 “K101(22q11.21)”, 4 “K10(5q33.3)”, 5 “K106(3q13.2)”, 6 “K115(8p23.1)”, 7 “K37(11q23.3)”, 8 “K102(1q22)”, 9 “K108(7p22.1)”, 10 “HKc10-B(10q24.2)”, 11 “K41(12q14.1)”, 12 “K109(6q14.1)” and 13 “KI(3q21.2)”). Out of the 66 full-length or nearly full-length *HERV-K(HML-2)* proviruses present in the human genome [1], a subset of 11 were found to be expressed in patterns, which varied from cell line to cell line (Table 1). More activated loci may be detected using optimized primers [28], deep sequencing techniques [29] as well as more cell lines. Notably, all transcribed loci belong to the LTR5Hs subgroup of *HERV-K(HML-2)* proviruses. Interestingly, phylogenetic classifications have shown that all human-specific retroviral integrations fall into this proviral subgroup [1]. Indeed, ten of the expressed proviruses were human-specific, while *K37(11q23.3)* may also be present in the genomes of great apes. Five of the re-activated proviruses belonged to type 1 and six to type 2 genotypes, respectively, but their number and expression levels varied between

**Table 1 Relative cloning frequencies of *HERV-K(HML-2)* loci transcribed in ESC, iPSC and ECC lines**

Alias	Type	ORF	ESC			iPSC			iPSC			ECC		
			BG01	H1	H9	MRC	iPS7	MRC	MSC	MSC	hFib2	hFib2	GH	NCCIT
K101(22q11.21) ERVK-24	1	g/n	64	60	57	69	61	56	88	62	39	75	16	29
K10(5q33.3) ERVK-10	1	g/prt/n	-	26	7,3	8	23	5,5	6	-	22	8,5	21	-
K109(6q14.1) ERVK-9	2	g/prt/e/r	-	7	7,3	-	8	-	-	-	-	-	-	42
K106(3q13.2) ERVK-3	1	g/n	-	-	-	-	-	5,5	-	8	11	-	5	-
K37(11q23.3) ERVK-20	1	g/prt/n	36	-	14	15	8	22	-	15	16	-	-	-
HKc10-B(10q24.2) ERVK-17	2	g/r	-	7	7	-	-	11	-	-	6	-	-	-
KI(3q21.2) ERVK-4	2	r	-	-	-	8	-	-	6	-	6	-	-	-
K115(8p23.1) ERVK-8	2	pol/e/r	-	-	-	-	-	-	-	15	-	-	-	-
K41(12q14.1) ERVK-21	2	g/prt/e/r	-	-	7,3	-	-	-	-	-	-	-	-	-
K108(7p22.1) ERVK-6	2	g/prt/e/r	-	-	-	-	-	-	-	-	-	16,5	11	29
K102(1q22) ERVK-7	1	n	-	-	-	-	-	-	-	-	-	-	47	-

Provirus are designated by name and chromosomal locus, by type and putative open reading frames (ORF). For each cell line the relative cloning frequencies of the respective *HERV-K(HML-2)* loci are given as % (number of sequences assigned to the locus divided by the total number of sequences generated from the cDNA sample). 14 clones were generated and analyzed for BG01, 2102Ep, H9; 15 for H1; 13 for MRCiPS7, MRCiPS20, hFib2iPS4; 17 for MSCiPS3; 18 for hFib2iPS5; 19 for MSCiPS1 and NCCIT, 24 for GH. Open reading frames for Gag (g), Protease (prt) Envelope (e), Rec (r) NP9 (n).

individual ESC/iPSC and ECC cell lines. Such variations in *HERV-K(HML-2)* proviral transcription profiles are commonly observed in somatic malignant and non-malignant tissues and cell lines [10,28] indicating a somewhat stochastic re-activation mechanism which may reflect varying chromatin dynamics [30]. By contrast, we observed constant and efficient transcription of the type 1 provirus *K101(22q11.21)* in all pluripotent stem cell lines tested, suggesting a more directed re-activation. *K101(22q11.21)*, *K37(11q23.3)* and *K10(5q33.3)* encode *gag* and *protease* genes and may account for the protein expression detected, e.g. in the H9 and hFib2-iPS5 lines (Figure 1D). Transcription of one or the other type 2 locus was detected in the ESC/iPSC lines, but only at low level. This is in contrast to the observed constant up-regulation of *K108(7p22.1)* expression exclusively in the malignant ECC lines. Notably, a recent survey of *HERV-K(HML-2)* proviruses transcribed in melanomas in comparison to melanocytes also demonstrated *K108(7p22.1)* derived mRNA only in melanomas but not in the non-malignant precursor cells [28].

## Conclusion

The endogenous betaretrovirus group *HERV-K(HML-2)* is unique in its potential to code for viral and accessory proteins. We observed, in slightly varying patterns, re-activation at the RNA and protein levels of certain human specific, protein encoding *HERV-K(HML-2)* proviruses with promoter competent LTR sequences in pluripotent ESCs, iPSCs, and ECCs. The surprisingly constant activation of *K101(22q11.21)* across all cell lines tested may indicate a particular function in or association with pluripotency. We detected *K108(7p22.1)* only in the malignant ECC lines. This corresponds to up-regulated *K108(7p22.1)* transcription described in other germ cell tumours, in brain tumours but not in normal brain [10] as well as in malignant melanoma [28] but not in melanocytes. *HERV-K(HML-2)* proviruses were rapidly silenced upon embryoid body differentiation. Re-activation of this HERV group thus represents another marker for the undifferentiated state of pluripotent stem cells.

Active type 2 proviruses produce Rec protein, which supports cell transformation *in vitro* and germ line carcinoma *in situ* in transgenic mice [7,31]. Type 1 proviruses produce Np9 protein [4]. Both Rec and Np9 interact with transcriptional regulators. For example, Rec and Np9 bind the MYC repressor PLZF resulting in overexpression of MYC [6] and Np9 can bind to LNX [8] which might influence the activity of the NOTCH pathway. MYC and NOTCH are often involved in carcinogenesis but are also important players in the signalling networks controlling self-renewal, pluripotency and differentiation [32]. Since there are substantial differences between the cell cycle regulation of murine and human pluripotent

stem cells [21], it is intriguing to speculate that Rec and Np9, which are not encoded by rodent ERVs, might play positive roles in human ESC/iPSCs. The observation that Rec and Np9 encoding *HERV-K(HML-2)* proviruses were preferentially activated in pluripotent stem cells and that their expression was simultaneously silenced upon differentiation independent of their chromosomal localization is in favour of such an idea.

## Additional files

**Additional file 1:** "Materials and Methods".

**Additional file 2:** "Alignments".

**Additional file 3:** "K101(22q11.21)".

**Additional file 4:** "K10(5q33.3)".

**Additional file 5:** "K106(3q13.2)".

**Additional file 6:** "K115(8p23.1)".

**Additional file 7:** "K37(11q23.3)".

**Additional file 8:** "K102(1q22)".

**Additional file 9:** "K108(7p22.1)".

**Additional file 10:** "HKc10-B(10q24.2)".

**Additional file 11:** "K41(12q14.1)".

**Additional file 12:** "K109(6q14.1)".

**Additional file 13:** "Kl(3q21.2)".

## Competing interests

The authors declare that no competing interests exist.

## Authors' contributions

NVF, SL and RL conceived the study and performed the analyses. NVF did *HERV-K(HML-2)* cloning, performed the sequence analysis and did the immunoblot assay. SL performed cell culture, embryoid body differentiation and RT-PCR analysis. GQD supplied the cells. ZI and GQD financially supported the study. JL helped interpret the results. NVF, SL, JL and RL wrote the manuscript. All authors have read and approved the submission of the manuscript.

## Acknowledgements

K. Boller (Paul-Ehrlich-Institute, Langen, Germany) has kindly provided the HERMA6/7 antibodies. We thank Christiane Tondera and Heike Strobel (Paul-Ehrlich-Institute, Langen, Germany) for excellent technical assistance. Also, we would like to express our gratitude to G. Schumann and S. Klawitter (Paul-Ehrlich-Institute, Langen, Germany) for stimulating discussions and K. Cichutek (President of the Paul-Ehrlich-Institute, Langen, Germany) for his constant support.

## Author details

<sup>1</sup>Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Str. 51-59, D- 63225 Langen, Germany. <sup>2</sup>Division of Pediatric Hematology and Oncology, Children's Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. <sup>3</sup>Present address: Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, D- 13125 Berlin, Germany. <sup>4</sup>Mobile DNA, Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, D- 13092 Berlin, Germany.

Received: 27 March 2013 Accepted: 29 September 2013

Published: 24 October 2013

## References

1. Subramanian RP, Wildschutte JH, Russo C, Coffin JM: Identification, characterization, and comparative genomic distribution of the *HERV-K (HML-2)* group of human endogenous retroviruses. *Retrovirology* 2011, **8**:90.

2. Fuchs NV, Kraft M, Tondera C, Hanschmann KM, Lower J, Lower R: Expression of the human endogenous retrovirus group HML-2/HERV-K does not depend on canonical promoter elements but is regulated by the transcription factors Sp1 and Sp3. *J Virol* 2011, **85**:3436–3448.
3. Magin C, Lower R, Lower J: cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K. *J Virol* 1999, **73**:9496–9507.
4. Armbruester V, Sauter M, Krautkraemer E, Meese E, Kleiman A, Best B, *et al*: A novel gene from the human endogenous retrovirus K expressed in transformed cells. *Clin Cancer Res* 2002, **8**:1800–1807.
5. Kaufmann S, Sauter M, Schmitt M, Baumert B, Best B, Boese A, *et al*: Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. *J Gen Virol* 2010, **91**:1494–1502.
6. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N: Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. *J Virol* 2007, **81**:5607–5616.
7. Boese A, Sauter M, Galli U, Best B, Herbst H, Mayer J, *et al*: Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. *Oncogene* 2000, **19**:4328–4336.
8. Armbruester V, Sauter M, Roemer K, Best B, Hahn S, Nty A, *et al*: Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. *J Virol* 2004, **78**:10310–10319.
9. Hanke K, Chudak C, Kurth R, Bannert N: The Rec protein of HERV-K(HML-2) upregulates androgen receptor activity by binding to the human small glutamine-rich tetratricopeptide repeat protein (hSGT). *Int J Cancer* 2013, **132**:556–567.
10. Flockerzi A, Ruggieri A, Frank O, Sauter M, Maldener E, Kopfer B, *et al*: Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project. *BMC Genomics* 2008, **9**:354.
11. Seifarth W, Frank O, Zeifelder U, Spiess B, Greenwood AD, Hehlmann R, *et al*: Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. *J Virol* 2005, **79**:341–352.
12. Kleiman A, Senyuta N, Tryakin A, Sauter M, Karseladze A, Tjulandin S, *et al*: HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors. *Int J Cancer* 2004, **110**:459–461.
13. Wang-Johanning F, Liu J, Rycak K, Huang M, Tsai K, Rosen DG, *et al*: Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. *Int J Cancer* 2007, **120**:81–90.
14. Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, *et al*: Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. *Cancer Res* 2006, **66**:1658–1663.
15. Hahn S, Ugurel S, Hanschmann KM, Strobel H, Tondera C, Schadendorf D, *et al*: Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. *AIDS Res Hum Retroviruses* 2008, **24**:717–723.
16. Wang-Johanning F, Rycak K, Plummer JB, Li M, Yin B, Frerich K, *et al*: Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. *J Natl Cancer Inst* 2012, **104**:189–210.
17. Lower R: The pathogenic potential of endogenous retroviruses: facts and fantasies. *Trends Microbiol* 1999, **7**:350–356.
18. Lower R, Boller K, Hasenmaier B, Korbmayer C, Muller-Lantzsch N, Lower J, *et al*: Identification of human endogenous retroviruses with complex mRNA expression and particle formation. *Proc Natl Acad Sci U S A* 1993, **90**:4480–4484.
19. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, *et al*: Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 2008, **451**:141–146.
20. Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, *et al*: Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. *Nat Genet* 2010, **42**:1113–1117.
21. Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell* 2008, **132**:567–582.
22. Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I, *et al*: The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. *Hum Mol Genet* 2006, **15**:1894–1913.
23. Chen G, Gulbranson DR, Yu P, Hou Z, Thomson JA: Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. *Stem Cells* 2012, **30**:623–630.
24. Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, *et al*: Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. *Cell* 2011, **144**:439–452.
25. Santoni FA, Guerra J, Luban J: HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency. *Retrovirology* 2012, **9**:111.
26. Wissing S, Munoz-Lopez M, Macia A, Yang Z, Montano M, Collins W, *et al*: Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. *Hum Mol Genet* 2012, **21**:208–218.
27. Ruprecht K, Ferreira H, Flockerzi A, Wahl S, Sauter M, Mayer J *et al*: Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21. *J Virol* 2008, **82**:10008–10016.
28. Schmitt K, Reichrath J, Roesch A, Meese E, Mayer J: Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma. *Genome Biol Evol* 2013, **5**:307–328.
29. Paces J, Huang YT, Paces V, Ridl J, Chang CM: New insight into transcription of human endogenous retroviral elements. *N Biotechnol* 2013, **30**:314–318.
30. Vinuelas J, Kaneko G, Coulon A, Vallin E, Morin V, Mejia-Pous C, *et al*: Quantifying the contribution of chromatin dynamics to stochastic gene expression reveals long, locus-dependent periods between transcriptional bursts. *BMC Biol* 2013, **11**:15.
31. Galli UM, Sauter M, Lecher B, Maurer S, Herbst H, Roemer K, *et al*: Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors. *Oncogene* 2005, **24**:3223–3228.
32. Singh AM, Dalton S: The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. *Cell Stem Cell* 2009, **5**:141–149.

doi:10.1186/1742-4690-10-115

**Cite this article as:** Fuchs *et al*: Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. *Retrovirology* 2013 **10**:115.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

